Longterm Retention Rate and Risk Factors for Adalimumab Discontinuation Due To Efficacy and Safety in Japanese Patients with Rheumatoid Arthritis: An Observational Cohort Study

作者：Hattori Yosuke^*; Kojima Toshihisa; Kaneko Atsushi; Kida Daihei; Hirano Yuji; Fujibayashi Takayoshi; Terabe Kenya; Yabe Yuichiro; Miyake Hiroyuki; Kato Takefumi; Takagi Hideki; Hayashi Masatoshi; Ito Takayasu; Kanayama Yasuhide; Oguchi Takeshi; Takahashi Nobunori; Ishikawa Hisato; Funahashi Koji; Ishiguro Naoki

来源：Journal of Rheumatology, 2016, 43(8): 1475-1479.

DOI：10.3899/jrheum.151006

• ADALIMUMAB
• RHEUMATOID ARTHRITIS
• EFFICACY
• SAFETY
• RETENTION RATE
• DISCONTINUATION

Objective. To evaluate the rates of retention and discontinuation of adalimumab (ADA) due to efficacy and safety in Japanese patients with rheumatoid arthritis (RA).
Methods. All patients with RA (n = 476) who were treated with ADA in the Tsurumai Biologics Communication Registry were enrolled.
Results. The retention rate of ADA was 46% at 5 years. When focusing on insufficient efficacy, previous biologics use and high baseline disease activity were significant risk factors for up to 1 year. Methotrexate (MTX) use was a significantly low risk factor after 1 year of treatment.
Conclusion. Concomitant MTX contributes to the longterm efficacy of ADA therapy.

• 出版日期2016-8